 |
|
U of T researchers create microchip that can detect type and severity of cancer
September 28, 2009TORONTO, ON - U of T researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment.
Their groundbreaking work, reported Sept. 27 in Nature Nanotechnology heralds an era when sophisticated molecular diagnostics will become commonplace.
"This remarkable innovation is an indication that the age of nanomedicine is dawning," says Professor David Naylor, president of the University of Toronto and a professor of medicine. "Thanks to the breadth of expertise here at U of T, cross-disciplinary collaborations of this nature make such landmark advances possible."
The researchers' new device can easily sense the signature biomarkers that indicate the presence of cancer at the cellular level, even though these biomolecules - genes that indicate aggressive or benign forms of the disease and differentiate subtypes of the cancer - are generally present only at low levels in biological samples. Analysis can be completed in 30 minutes, a vast improvement over the existing diagnostic procedures that generally take days.
"Today, it takes a room filled with computers to evaluate a clinically relevant sample of cancer biomarkers and the results aren't quickly available," says Shana Kelley, a professor in the Leslie Dan Faculty of Pharmacy and the Faculty of Medicine, who was a lead investigator on the project and a co-author on the publication.
"Our team was able to measure biomolecules on an electronic chip the size of your fingertip and analyse the sample within half an hour. The instrumentation required for this analysis can be contained within a unit the size of a BlackBerry."
Kelley, along with engineering professor Ted Sargent - a fellow lead investigator and U of T's Canada Research Chair in Nanotechnology - and an interdisciplinary team from Princess Margaret Hospital and Queen's University, found that conventional, flat metal electrical sensors were inadequate to sense cancer's particular biomarkers. Instead, they designed and fabricated a chip and decorated it with nanometre-sized wires and molecular "bait."
"Uniting DNA - the molecule of life - with speedy, miniaturized electronic chips is an example of cross-disciplinary convergence," says Sargent. "By working with outstanding researchers in nanomaterials, pharmaceutical sciences, and electrical engineering, we were able to demonstrate that controlled integration of nanomaterials provides a major advantage in disease detection and analysis."
The speed and accuracy provided by their device is welcome news to cancer researchers.
"We rely on the measurement of biomarkers to detect cancer and to know if treatments are working," says Dr. Tom Hudson, president and scientific director of the Ontario Institute for Cancer Research. "The discovery by Dr. Kelley and her team offers the possibility of a faster, more cost-effective technology that could be used anywhere, speeding up diagnosis and helping to deliver a more targeted treatment to the patient."
The team's microchip platform has been tested on prostate cancer, as described in a paper published in ACS Nano, and head and neck cancer models. It could potentially be used to diagnose and assess other cancers, as well as infectious diseases such as HIV, MRSA and H1N1 flu.
"The system developed by the Kelley/Sargent team is a revolutionary technology that could allow us to track biomarkers that might have significant relevance to cancer, with a combination of speed, sensitivity, and accuracy not available with any current technology," says Dr. Fei-Fei Liu, a radiation oncologist at Princess Margaret Hospital and Head of Applied Molecular Oncology Division, Ontario Cancer Institute. "This type of approach could have a profound impact on the future management for our cancer patients."
University of Toronto
The researchers' new device can easily sense the signature biomarkers that indicate the presence of cancer at the cellular level, even though these biomolecules - genes that indicate aggressive or benign forms of the disease and differentiate subtypes of the cancer - are generally present only at low levels in biological samples. Analysis can be completed in 30 minutes, a vast improvement over the existing diagnostic procedures that generally take days.
"Today, it takes a room filled with computers to evaluate a clinically relevant sample of cancer biomarkers and the results aren't quickly available," says Shana Kelley, a professor in the Leslie Dan Faculty of Pharmacy and the Faculty of Medicine, who was a lead investigator on the project and a co-author on the publication.
"Our team was able to measure biomolecules on an electronic chip the size of your fingertip and analyse the sample within half an hour. The instrumentation required for this analysis can be contained within a unit the size of a BlackBerry."
Kelley, along with engineering professor Ted Sargent - a fellow lead investigator and U of T's Canada Research Chair in Nanotechnology - and an interdisciplinary team from Princess Margaret Hospital and Queen's University, found that conventional, flat metal electrical sensors were inadequate to sense cancer's particular biomarkers. Instead, they designed and fabricated a chip and decorated it with nanometre-sized wires and molecular "bait."
"Uniting DNA - the molecule of life - with speedy, miniaturized electronic chips is an example of cross-disciplinary convergence," says Sargent. "By working with outstanding researchers in nanomaterials, pharmaceutical sciences, and electrical engineering, we were able to demonstrate that controlled integration of nanomaterials provides a major advantage in disease detection and analysis."
The speed and accuracy provided by their device is welcome news to cancer researchers.
"We rely on the measurement of biomarkers to detect cancer and to know if treatments are working," says Dr. Tom Hudson, president and scientific director of the Ontario Institute for Cancer Research. "The discovery by Dr. Kelley and her team offers the possibility of a faster, more cost-effective technology that could be used anywhere, speeding up diagnosis and helping to deliver a more targeted treatment to the patient."
The team's microchip platform has been tested on prostate cancer, as described in a paper published in ACS Nano, and head and neck cancer models. It could potentially be used to diagnose and assess other cancers, as well as infectious diseases such as HIV, MRSA and H1N1 flu.
"The system developed by the Kelley/Sargent team is a revolutionary technology that could allow us to track biomarkers that might have significant relevance to cancer, with a combination of speed, sensitivity, and accuracy not available with any current technology," says Dr. Fei-Fei Liu, a radiation oncologist at Princess Margaret Hospital and Head of Applied Molecular Oncology Division, Ontario Cancer Institute. "This type of approach could have a profound impact on the future management for our cancer patients."
University of Toronto
Biomarkers Current Events and Biomarkers News RSSSaliva proteins change as women age
In a step toward using human saliva to tell whether those stiff joints, memory lapses, and other telltale signs of aging are normal or red flags for disease, scientists are describing how the protein content of women's saliva change with advancing age.
Elevated biomarkers lead to diminished quality of life in heart attack patients post-discharge
Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study.
Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.
Neuroimaging provides insights into new treatment options for Alzheimer's disease
With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense.
Expectant moms, babies subjects of new Singapore study to prevent obesity and diabetes in adults
Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.
New finding suggests prostate biopsy is not always necessary
Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.
Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
New Notre Dame study provides insights into the molecular basis of tumor cell behavior
A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression.
Does green tea prevent cancer? Evidence continues to brew, but questions remain
Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.
Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.
More Biomarkers Current Events and Biomarkers News Articles
 |
Biomarkers: The 10 Keys to Prolonging Vitality by William Evans (Author) Exciting new evidence from the USDA Human Nutrition Research Center on Aging at Tufts University has demonstrated that the body's decline is due not to the passing of years but to the combined effects of inactivity, poor nutrition, and illness -- much of which can be controlled. This breakthrough study shows that regardless of your age or present physical condition, the aging process can be slowed -- or even reversed! The authors have identified ten "biomarkers," the key physiological factors associated with prolonged youth and vitality: * lean body (muscle) mass |
 |
Biomarkers: 10 Determinants of Aging You Can Control by William Evans (Author), Irwin Rosenberg (Author) |
|
Cancer Biomarkers by Ios Press Original research findings (and reviews solicited by the Editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. | |
 |
Biomarkers of Disease: An Evidence-Based Approach by Andrew K. Trull (Editor), Lawrence M. Demers (Editor), David W. Holt (Editor), Atholl Johnston (Editor), J. Michael Tredger (Editor), Christopher P. Price (Editor) This new publication takes a critical, evidence-based look at the efficacy of new diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. The use of biomarkers is growing, with a steady stream of new products being brought out by the pharmaceutical industry. However, in many cases the evidence which supports the use of these new methods as opposed to traditional biochemical tests has not yet been demonstrated, and it is intended that this volume will help clarify the strengths and weaknesses of using these biomarkers across a wide range of applications and in the various organs of the body. This approach will provide an invaluable overview of the diverse applications of biomarkers in medicine. |
 |
Biomarkers by S.V.S. Rana (Author), Sung-Eun Lee (Author) |
 |
Biomarker Methods in Drug Discovery and Development (Methods in Pharmacology and Toxicology) by Feng Wang (Editor) Within the pharmaceutical industry, the improvement of drug discovery and development efficiency and the expected personalization of medicine have become vitally important issues. In Biomarker Methods in Drug Discovery and Development, expert researchers provide a tool box for those who have a general interest in biomarker research and for those currently specializing in certain technologies but desiring an understanding of other available methodologies. Its chapters include validated, mature methods as well as new, incredibly promising protocols which aim to apply multiple technologies at different molecular levels in order to surmount the monumental and complex task of transforming the pharmaceutical research and development processes. As a volume in the Methods in Pharmacology and... |
 |
Cancer Biomarkers: Analytical Techniques for Discovery (Wiley - Interscience Series on Mass Spectrometry) by Mahmoud H. Hamdan (Author), Dominic M. Desiderio (Series Editor), Nico M. Nibbering (Series Editor) Tools, techniques, and progress in cancer biomarkers discovery The completion of a number of gene sequencing projects, recent advances in genomic and proteomic technologies, and the availability of powerful bioinformatics tools have led to promising new avenues and approaches in the search for cancer biomarkers. This book provides a comprehensive overview of current methodologies and technologies. It discusses biomarker discovery as a whole, rather than focusing on one specific marker or cancer. With information on both existing and potential biomarkers, Cancer Biomarkers: Analytical Techniques for Discovery: * Provides insights into the current technological platforms for biomarker discovery, including mass spectrometry combined with multidimensional chromatography,... |
 |
The Biomarker Guide: Volume 2, Biomarkers and Isotopes in Petroleum Systems and Earth History by K. E. Peters (Author), C. C. Walters (Author), J. M. Moldowan (Author) The second volume itemizes parameters used to genetically correlate petroleum and interpret thermal maturity and extent of biodegradation. It documents most known petroleum systems by geologic age throughout Earth history. |
 |
The Biomarker Guide: Volume 1, Biomarkers and Isotopes in the Environment and Human History (v. 1) by K. E. Peters (Author), C. C. Walters (Author), J. M. Moldowan (Author) Biomarkers are compounds found in crude oil with structures inherited from once-living organisms. They persist in oil spills, refinery products and archaeological artifacts, and can be used to identify the origin, geological age and environmental conditions prevalent during their formation and alteration. These two volumes will be an invaluable resource for geologists, petroleum geochemists, biogeochemists, environmental and forensic scientists, natural product chemists and archaeologists. The first of two volumes of The Biomarker Guide discusses the origins of biomarkers and introduces basic chemical principles relevant to their study. It goes on to discuss analytical techniques, and the applications of biomarkers in environmental and archaeological problems. |
 |
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary (Forum on Neuroscience and Nervous System Disorders) by Forum on Neuroscience and Nervous System Disorders (Author), Institute of Medicine (Author), Miriam Davis (Editor), Sarah Hanson (Editor), Bruce Altevogt (Editor) Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine[trademark] Forum on Neuroscience and Nervous System Disorders convened a public workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships.The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact.... |
| © 2009 BrightSurf.com |